Regulatory Update: FDA Steps Up Debarment and Disqualification Efforts

| 01 September 2009

The US Food and Drug Administration (FDA) recently enhanced its procedures for debarment and disqualification of noncompliant investigators and others as another step toward protecting clinical trial participants and ensuring the safety and effectiveness of the medical products marketed in the US.

 

© 2022 Regulatory Affairs Professionals Society.

Discover more of what matters to you

No taxonomy